- Personalis Inc PSNL and Moderna Inc MRNA have signed a new agreement to continue using the Personalis NeXT Platform as part of upcoming clinical studies of mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck & Co Inc MRK.
- The platform, also utilized in the vaccine candidate's Phase 2b study, will be used to sequence genomic information from a patient's tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.
- In January, Personalis approved a reduction in its workforce by up to approximately 30% to reduce operating costs and improve operating efficiency.
- The company estimates that it will incur charges of approximately $3 million for severance payments and employee benefits, primarily in the first quarter of 2023.
- Price Action: PSNL shares are up 26.80% at $3.86 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
